Impact of Omalizumab Treatment Withdrawal After 24 and 48 Weeks in Patients with Chronic Idiopathic Urticaria: Results From the XTEND-CIU Study

Omalizumab significantly reduces the frequency/severity of CIU symptoms. However, as 24 weeks represents the longest treatment period in pivotal trials, uncertainty exists regarding optimal treatment duration and clinical worsening predictors following cessation. (Source: Journal of Allergy and Clinical Immunology)

from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader http://bit.ly/2Du149b